Physician profile
Elaine S Edmonds
NPI 1164437620
$610,062.35
in general payments reported to CMS, 2019-2025
23 companies · $62K in 2025
The $62K reported for 2025 was more than what 97% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $191K · 2020: $52K · 2021: $85K · 2022: $85K · 2023: $81K · 2024: $54K · 2025: $62K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $161K · Travel and Lodging: $14K · Honoraria: $12K · Food and Beverage: $9,040 · Consulting Fee: $1,253 · Education: $55.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $160,688.50 |
| Travel and Lodging | $14,454.24 |
| Honoraria | $11,700.00 |
| Food and Beverage | $9,040.16 |
| Consulting Fee | $1,253.00 |
| Education | $55.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $280,279.63 | 2019-2025 | Mavenclad, Mavenclad |
| Biogen, INC. | $138,669.95 | 2019-2023 | Tysabri, Tysabri, Vumerity |
| Genzyme Corporation | $117,300.92 | 2019-2025 | |
| Horizon Therapeutics Plc | $42,232.90 | 2021-2023 | Uplizna |
| Amgen INC. | $30,098.89 | 2024-2025 | Uplizna |
| Sanofi-Aventis U.S. LLC | $217.53 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $173.30 | 2022-2024 | |
| Abbvie INC. | $160.22 | 2023-2025 | Botox, Ubrelvy, Qulipta |
| Genentech USA, INC. | $149.35 | 2019 | |
| Alexion Pharmaceuticals, INC. | $118.76 | 2021-2025 | Ultomiris |
| Tg Therapeutics, INC. | $101.71 | 2024 | |
| Banner Life Sciences, LLC | $98.83 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.54 | 2024 | |
| Neurocrine Biosciences, INC. | $64.85 | 2022-2023 | Ingrezza |
| Argenx US, INC. | $57.57 | 2023-2024 | Vyvgart Hytrulo, Vyvgart |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $51.61 | 2023 | Zeposia |
| Sk Life Science, INC. | $44.69 | 2024 | |
| Csl Behring | $42.48 | 2021 | |
| Aesculap, INC. | $40.48 | 2019 | |
| Janssen Pharmaceuticals, INC | $23.28 | 2022 | |
| Lilly USA, LLC | $22.73 | 2025 | Kisunla, Amyvid |
| Jazz Pharmaceuticals INC. | $21.93 | 2022 | |
| Acadia Pharmaceuticals INC | $14.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elaine Edmonds listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.